News ReleaseView printer-friendly version << Back
AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings
The article entitled "Patient and Healthcare Professional Satisfaction Ratings and Safety Profile of Sufentanil Sublingual Tablets for Treatment of Acute Pain: A Pooled Demographic Analysis" by lead author
The global satisfaction analysis included a total of 283 patients who had completed the assessments as well as their healthcare professionals who had dosed DSUVIA in the clinical trials. The patient global assessment (PGA) and the healthcare professional global assessment (HPGA) scale is a 4-point scale of "poor", "fair", "good", or "excellent" for the method of pain control and these scores were assessed across the patient demographic subgroups of age, body-mass index (BMI), sex and race. Adverse events across these same demographic subpopulations were also assessed. Key findings included the following:
- The highest percent of excellent scores across all evaluations was for the HPGA in older patients (≥ 65 years), with 61% of healthcare professionals rating pain control in these older patients as "excellent"; there were no statistical differences across older versus younger patients for either PGA or HPGA.
- High ratings by both low (< 30 kg/m2) and high BMI (≥ 30 kg/m2) patients on the PGA were observed with 86% and 85%, respectively, rating "good" or "excellent" on the PGA; similar ratings were seen with the HPGA for these subgroups and no statistical differences were observed between the groups.
- Male and female patients had high ratings on both the PGA and HPGA, with HPGA scores statistically higher for male patients over female patients (p=0.023), while PGA scores were similar and not statistically different.
- There were no statistical differences among races for either the PGA or HPGA with each of these subpopulations scoring high percentages of "good" or "excellent" ratings.
DSUVIA was well tolerated throughout the Phase 3 studies with 68% of the 323 total patients evaluated not experiencing any DSUVIA-related adverse events. Adverse events occurring in ≥ 2% of the patients were nausea (22.9%), headache (5.0%), dizziness (4.0%) and vomiting (3.1%). Importantly, the adverse events of decreased oxygen saturation and somnolence were low, occurring in 1.5% and 1.2% of the patients, respectively. Study limitations included a higher enrollment of younger compared to older patients, and opioid-tolerant patients were excluded.
"The results from this pooled analysis of the DSUVIA Phase 3 trials mirror the impressive clinical outcomes that I observed during dosing of DSUVIA in these clinical trial patients as well as patients in my current anesthesia practice," said
"The consistency of analgesia across the demographic subgroups was notable, especially given the single 30-mcg dose for all patients," said Dr. Pamela Palmer, AcelRx Chief Medical Officer and co-founder. "The patients, whether old or young, obese or non-obese, and regardless of sex or race, reported overall high ratings for the global assessment of pain control and their healthcare professionals also rated these patients with high scores among the different subgroups."
These Phase 3 studies were funded by AcelRx and the Clinical and Rehabilitative Medicine Research Program (CRMRP) of the
About DSUVIA (sufentanil sublingual tablet), 30 mcg
DSUVIA®, known as DZUVEO™ in
View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-clinical-data-reporting-high-ratings-for-healthcare-professional-and-patient-satisfaction-following-use-of-dsuvia-for-acute-pain-in-hospital-settings-301255704.html
Investor Contacts: Raffi Asadorian, CFO, AcelRx, firstname.lastname@example.org, or Brian Korb, Solebury Trout, 646-378-2923, email@example.com